---
document_datetime: 2023-09-21 17:11:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/noxafil-epar-procedural-steps-taken-authorisation_en.pdf
document_name: noxafil-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4197126
conversion_datetime: 2025-12-20 00:52:52.564836
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Schering-Plough  Europe  submitted  on  2  July  2004  an  application  for  Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Noxafil, through  the  centralised  procedure.  After  agreement  by  the  CHMP  on  20 March  2004  this  medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Dr Ian Hudson

Co-Rapporteur: Dr Eric Abadie

## Scientific Advice:

The applicant received Scientific Advice from the CHMP on 25 April 2001. The Scientific Advice pertained to clinical aspects of the dossier.

## Licensing status:

A new application was filed in the following countries: USA.

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 2 July 2004.
- The procedure started on 19 July 2004.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 1 October 2004. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 5 October 2004.
- During the meeting on 15 - 18 November 2004, the CHMP agreed on the consolidated List of Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions was  sent  to  the applicant on 18 November 2004.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 15 March 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 28 April 2005.
- During the CHMP meeting on 23 - 26 May 2005, the CHMP agreed on a List of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant submitted the responses to the CHMP List of outstanding issues on 15 June 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of outstanding Issues to all CHMP members on 5 July 2005.
- During the meeting on 25 - 27 July 2005, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  to  Noxafil  on  27  July  2005.  The  applicant  provided  the  letter  of undertaking on the follow-up measures to be fulfilled post-authorisation on 26 July 2005.
- The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decisions on 25 October 2005.